The Women's Health Research Gap: How Women Were Left Out, and Why It Matters

For most of the twentieth century, medical research studied men and assumed the findings would transfer to women. They often did not. Women were formally discouraged, and in many cases excluded, from clinical trials until the early 1990s, which means large parts of what medicine "knew" about disease, dosing, and drug safety were built on male bodies. The gap this created is not a matter of opinion. It shows up in drug labels, in diagnostic delays, and in the plain fact that for some common conditions we still have less high-quality evidence in women than in men. Closing that gap is one of the more important, and more fixable, problems in modern medicine.

I write about this as a physician-scientist and as a grant reviewer for the Pivotal Philanthropies Action for Women's Health initiative, where part of the work is judging whether proposed research is rigorous and answers a question that actually needs answering. That vantage point makes the history and the stakes hard to ignore.

How women were left out

The exclusion was not an accident of neglect. It was, for a time, official policy. In 1977 the U.S. Food and Drug Administration issued guidance recommending that women "of childbearing potential" be kept out of early-phase drug trials. The language was sweeping. It applied even to women using contraception, unmarried women, and women whose partners had been sterilized. The stated motive was protective, shaped in part by the thalidomide tragedy of the preceding decade, when a drug taken for morning sickness caused severe birth defects. The instinct to shield a potential pregnancy was understandable. The consequence was that a large share of the adult female population was written out of the evidence base.

Researchers also excluded women for reasons of convenience. Hormonal cycles were treated as a nuisance variable that made data "messier," so male subjects were preferred because they were considered simpler to study. The result was a research culture in which the 70-kilogram man became the default human, and female physiology became an afterthought to be extrapolated later.

The policy changes that followed

Two changes in 1993 reset the terms. First, the FDA reversed its 1977 stance. Health officials characterized the earlier approach as paternalistic, and the agency issued new guidance calling for the study of sex differences in the clinical evaluation of drugs. Second, and more far-reaching, Congress passed the NIH Revitalization Act in 1993. For the first time it was a legal requirement, not a suggestion, that women and members of minority groups be included in federally funded clinical research. The law also directed that Phase III trials be designed so they could be analyzed for differences between the sexes, established the Office of Research on Women's Health within the NIH, and made clear that cost was not an acceptable reason for leaving women out.

These were structural fixes, and they mattered. But a policy that starts in 1993 cannot retroactively fill in decades of missing data. Inclusion on paper is also not the same as adequate representation or analysis in practice, and researchers still document trials that enroll too few women, or that fail to report results by sex at all.

Why sex differences actually matter

The case for including women is not only about fairness. It is about accuracy. Sex differences run deeper than reproductive organs and reach into how the body handles medication.

Physiology and drug handling

Body composition, kidney filtration, liver enzyme activity, and hormonal environment all differ, on average, between women and men, and each of these can change how a drug is absorbed, distributed, and cleared. One well-documented illustration entered the FDA's own labeling. In 2013 the agency revised the label for the sleep medication zolpidem to reflect that women, on average, clear the drug more slowly, so that next-morning blood levels could be high enough to impair driving in some of them. The same intake produced a different exposure in a female body. That change reframed a question the field should have been asking all along: how many other assumptions about a "standard" drug were set in populations that underrepresented women?

Different presentations, different evidence

Some conditions present differently by sex, which affects how quickly they are recognized. Sex-based differences in the symptoms of heart attack have been described for years, and when the "typical" picture is drawn from men, less familiar presentations in women can be missed or delayed. The lesson is not that women are a special case to be handled separately. It is that a drug or a disease studied in one group cannot be assumed to behave identically in another.

What evidence-based women's health looks like

A field that markets to women is not the same as a field that has evidence for women, and the distinction is worth holding onto. Evidence-based women's health means asking, for any test, drug, or intervention, whether it was actually studied in women, in what numbers, and whether the results were analyzed by sex rather than pooled and assumed.

The Women's Health Initiative is a useful example of what rigorous study buys, and how nuanced the answers can be. Its large randomized trials of postmenopausal hormone therapy overturned assumptions that had rested on weaker observational data, showing increased risks of certain outcomes such as stroke and blood clots in the studied regimens and populations, while later analyses pointed to how much timing and individual risk profile matter. The takeaway is deliberately not a recommendation for or against any therapy. It is that decisions of this kind belong to an individual and a qualified clinician who can weigh her specific situation, and that good trials give them real evidence to work with instead of extrapolation.

The same standard applies to the tests and products now marketed under the "women's health" and "hormone optimization" banners. The right questions are unglamorous. Was there a randomized human trial. Does the claim describe a disease or just a vague sense of wellness. Is the evidence from people, or from cells and animals dressed up to sound conclusive. A gap created by exclusion is not closed by marketing that skips the evidence step entirely.

This article is educational and not medical advice. For any decision about your own health, talk with your own clinician, who can account for your history and circumstances.